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Abstract
Background: Selective fetal growth restriction in monochorionic twin pregnancies is associated with an increased
risk of perinatal mortality and morbidity and represents a clinical dilemma. Interventions include expectant management
with early preterm delivery if there are signs of fetal compromise, selective termination of the compromised twin,
fetoscopic laser coagulation of the communicating placental vessels or termination of the whole pregnancy. Previous
studies evaluating interventions have reported many different outcomes and outcome measures. Such variation makes
comparing, contrasting, and combining results challenging, limiting ongoing research on this uncommon condition to
inform clinical practice. We aim to produce, disseminate, and implement a core outcome set for selective fetal growth
restriction research in monochorionic twin pregnancies.
Methods: An international steering group, including professionals, researchers, and lay experts, has been established to
oversee the development of this core outcome set. The methods have been guided by the Core Outcome Measures in
Effectiveness Trials Initiative Handbook.
Potential core outcomes will be developed by undertaking a systematic review of studies evaluating interventions for
selective fetal growth restriction in monochorionic twin pregnancies. Potential core outcomes will be entered into a
three-round Delphi survey and key stakeholders including clinical professionals, researchers, and lay experts will be invited
to participate. Repeated reflection and rescoring of individual outcomes should encourage group and
individual stakeholder convergence towards consensus outcomes which will be entered into a modified
Nominal Group Technique to finalize the core outcome set. Once core outcomes have been agreed, we will
establish standardized definitions and recommend high-quality measurement instruments for each outcome.
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Discussion: The development, dissemination, and implementation of a core outcome set for selective fetal
growth restriction should ensure that future research protocols select, collect, and report outcomes and outcome
measures in a standardized manner. Data synthesis will be possible on a broad level and rigorous implementation
should advance the quality of research studies and their effective use in order to guide clinical practice, improve
patient care, maternal, short-term perinatal outcomes, and long-term neurodevelopmental outcomes.
Trial registration: Core Outcome Measures in Effectiveness Trials (COMET) registration number: 998.
International Prospective Register of Systematic Reviews (PROSPERO) registration number: CRD42018092697. 18th April
2018.
Keywords: Selective fetal growth restriction, Selective intrauterine growth restriction, Core outcome set, Modified
Delphi method, Modified Nominal Group Technique, Consensus development study
Background
Twin pregnancies complicated by selective fetal growth
restriction (sFGR) are associated with increased perinatal
mortality and morbidity [1]. This pathology affects 10–
15% of monochorionic (MC) twin pregnancies and rep-
resents a management challenge due to the interdepend-
ence of twins connected via the placental vasculature
[2–5]. One particular challenge in MC twin pregnancies
complicated by sFGR is the risk of acute feto-fetal trans-
fusion in the event of demise or hypoxia and vascular
imbalance with profound hypotension in one twin caus-
ing death or neurological injury in the co-twin [6].
A classification according to the umbilical artery
Doppler findings in the smaller twin was proposed in
2007, where three types with variable prognosis were
identified [7]. Furthermore, we have recently published
a consensus agreement on the diagnostic criteria of
sFGR in twin pregnancies [8]. Although the overall
perinatal survival in pregnancies affected by type 1
sFGR (with positive end-diastolic flow in the umbilical
artery Doppler) is as high as 97%, the survival in sFGR
with absent or reversed end-diastolic flow in the umbil-
ical artery Doppler (types 2 and 3) is around 60 and
85%, respectively [3–5], with a high risk of intrauterine
demise that may be particularly unpredictable in type 3
sFGR [1, 7]. Possible interventions include expectant
management with early preterm delivery if there are
signs of fetal compromise and active fetal intervention,
which includes selective termination of the compro-
mised twin, fetoscopic laser coagulation of the commu-
nicating placental vessels or termination of the whole
pregnancy. Selective termination favors the outcome of
the larger twin, while fetoscopic laser coagulation of
the placental vessels can achieve survival of both twins
in select cases at the cost of a higher risk of mortality
and neurological complications in the larger co-twin [4,
5, 9, 10]. Clinicians and researchers face clinical uncer-
tainty regarding the optimal management of sFGR [3–
5]. Given the variation in outcome by classification, the
optimal management is likely to vary according to the
type and severity of sFGR, the distribution of placental
tissue and the timing of onset.
Given the high potential for morbidity and mortality
in these pregnancies, there is a need for robust guidance
on the safest and most effective course of management.
However, the large variation among the studies in the re-
ported outcomes, makes it difficult to compare results,
or combine the data from individual studies, limiting the
potential of research to guide clinical practice. Core out-
come sets are agreed, clearly defined minimum sets of
outcomes that can be measured in a standardized man-
ner and reported consistently [11]. Acknowledging that
inconsistencies in outcome reporting can be disruptive
to progress in our specialty, 78 editors of journals on
women’s health came together to form a consortium to
support the development, dissemination, and implemen-
tation of core outcome sets [12].
Our objective is to produce, disseminate, and implement
a core outcome set for sFGR in MC twin pregnancies.
Methods
The methods have been informed by the Core Outcome
Measures in Effectiveness Trials (COMET) Initiative
Handbook and other core outcome set development
studies relevant to women’s and newborn health, includ-
ing twin-to-twin transfusion syndrome, pre-eclampsia,
endometriosis, termination of pregnancy, and neonatal
medicine [11, 13–17]. This study protocol is reported in
accordance with Standard Protocol Items: Recommenda-
tions for Interventional Trials (SPIRIT) Guidelines (Add-
itional file 1). The stages of the development of the core
outcome set are shown in Fig. 1.
Prospective registration
This study has been registered with the International
Prospective Register of Systematic Reviews (PROSPERO)
(registration number: CRD42018092697 and The Core
Outcome Measures in Effectiveness Trials (COMET)
Initiative (registration number: 998).
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Steering Group
An international steering group, including professionals,
researchers, and women with lived experience of sFGR,
has been formed to guide the development of this core
outcome set. The Steering Group members were
approached and invited based on their expertise as clini-
cians and researchers in sFGR. Patient representatives
were approached as interested individuals who had pre-
viously contacted The Twin and Multiple Births Associ-
ation (TAMBA). The Steering Group has been
established to make decisions regarding the study’s
methods; for example, determining the scope of the core
outcome set, selecting appropriate consensus methods,
and developing the recruitment strategy. While the
Steering Group will oversee the process, further partici-
pants will be involved in the consensus-forming process
and anyone, anywhere is welcome to participate.
Scope of the core outcome set
This core outcome set will apply to all therapeutic inter-
ventions for sFGR. This will not be limited by the type
of intervention, the setting in which administered, or the
gestation at which provided. Selective fetal growth re-
striction will be defined according to the recently pub-
lished consensus agreement on the diagnostic criteria of
sFGR in twin pregnancies; the solitary finding of an esti-
mated fetal weight below the third centile in one of the
twins or at least two out of four of the following: (1) an
estimated fetal weight below the 10th centile in one of
the twins, (2) an abdominal circumference below the
10th centile in one of the twins, (3) an estimated fetal
weight discordance ≥ 25%, and (4) umbilical artery Dop-
pler pulsatility index > 95th centile in the smaller twin
[8]. However, as this consensus was only recently pub-
lished, studies that use other definitions, the commonest
is one twin with an estimated fetal weight less than the
10th centile, will be included. We are not seeking to
reach consensus on the standardization of other aspects
of study design or the definition or staging of sFGR.
Identifying potential core outcomes
We will conduct a systematic review to identify potential
core outcomes. The systematic review methods will be
informed by published systematic reviews identifying po-
tential core outcomes [18–23]. We will search the
Cochrane Central Register of Controlled Trials (CEN-
TRAL), EMBASE, and MEDLINE from inception to
January 2018 to identify all trials and observational stud-
ies reporting outcomes evaluating interventions for
sFGR using defined Medical Subject Headings (MeSH)
descriptor terms including sFGR and selective intrauter-
ine growth restriction. We will search unpublished gray
literature and ongoing trials and observational studies
using the same terms. The conduct of the systematic re-
view will adhere to standard systematic review methods
[24]. The population includes MC twin pregnancies
complicated by sFGR. The interventions include any
intervention used for the treatment of sFGR. The com-
parator will include any comparator treatment used for
the interventions of sFGR. Possible interventions include
alternative treatment, standard care, a placebo treatment
or no treatment. The outcomes will include all outcomes
reported in the included sFGR studies. We will include
all randomized controlled trials, quasi-randomized trials,
controlled before and after studies, interrupted time
series, and observational studies that report an outcome
Fig. 1 The stages of developing a core outcome set for selective fetal growth restriction
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following any intervention for sFGR. We will exclude
case reports, small case series, editorials, and review arti-
cles. No data or language limits will be applied.
All studies identified in the search will be screened
using the title and abstract. The full-text article will be
reviewed of all studies meeting the inclusion criteria and
those where this cannot be determined from the abstract
alone. Identified studies will be reviewed by two re-
viewers and any discrepancies resolved by discussion
with a third reviewer. The studies will be assessed using
a purposively developed Data Extraction Form to collect
the following information: year of publication, study de-
sign, sample size, intervention undertaken, outcomes,
and outcome measures.
We will report the systematic review with reference to
the Preferred Reporting Items for Systematic Reviews
and Meta-analyses (PRISMA) Statement for reporting
systematic reviews and meta-analyses of studies that
evaluate health care interventions [25]. All identified
outcomes will be entered into an outcome inventory and
organized into the following categories: survival out-
comes, fetal outcomes, short-term neonatal outcomes,
long-term neurodevelopmental outcomes (including be-
havioral outcomes and quality of life), obstetric out-
comes and surgical/operator outcomes. These outcomes
will be reviewed and discussed by the Steering Group
with particular emphasis on reducing duplication of out-
comes caused by varying terminologies and grouping
very similar outcomes together in order to make the
final outcome inventory clear and succinct. Following
agreement, the inventory will be entered into the modi-
fied Delphi method. The wording of the outcomes will
be decided in collaboration with the patient representa-
tives (TAMBA).
Determining core outcomes
The core outcomes will be determined by using a modi-
fied Delphi method. The Delphi method is an estab-
lished tool for achieving a convergence of opinion on a
particular subject by gathering data from respondents
with expert knowledge of that particular subject. It al-
lows consensus building by using a series of question-
naires to extract opinion from participants. Web-based
Delphi tools facilitate international data collection and
are largely considered acceptable to the user [26, 27]. All
categories of stakeholder, including health professionals,
researchers and people with lived experience of or ex-
pertise in sFGR will be invited to take part. By asking
participants to specify the stakeholder group that they
most identify with, we will be able to interpret the re-
sults of the survey both as a whole and by participant
background, and to identify any differences between the
groups. The recruitment strategy has been designed to
ensure that people with assorted experiences of sFGR
from diverse demographic backgrounds and geograph-
ical locations can be recruited. We will ask members of
an expert panel who have participated in the core out-
come set on twin-to-twin transfusion syndrome and
those who participated in the development of a consen-
sus on the diagnostic criteria of sFGR. Recruitment will
be facilitated by national and international patient orga-
nizations, including TAMBA, and national and inter-
national professional organizations, including the Royal
College of Obstetricians and Gynaecologists (RCOG),
the International Society of Ultrasound in Obstetrics
and Gynaecology (ISUOG), and the International Society
for Twin Studies (ISTS), advertising the study within
their newsletters, online forums, and social media feeds.
Potential participants will be able to register their inter-
est online and will be sent Delphi survey instructions
written in plain language. When participants register to
complete the survey, they will complete a questionnaire
recording demographic details; for example, age, ethnic
group, and country, and information pertaining to their
experiences or expertise of sFGR. We aim to recruit 18
participants for each stakeholder group. Participants
who fail to complete the Delphi survey will be asked
about their reasons for withdrawal. Only core members
of the Steering Group will have access to the study
dataset.
Round 1
All participants will be invited to register with the online
survey and will be allocated a unique identifier to enable
anonymization of their responses. They will be asked to
score individual outcomes on a 9-point Likert scale an-
chored between one (labeled “of limited importance for
making a decision”) and 9 (labeled “critical for making a
decision”). This scale was devised by the Grading of Rec-
ommendations Assessment, Development and Evalu-
ation (GRADE) Working Group to facilitate the ranking
of outcomes according to their importance and has been
adopted widely by core outcome set developers [28].
There will be an opportunity for participants to suggest
new outcomes and these will be considered by the Steer-
ing Group for inclusion in the second-round survey.
Round 2
All outcomes will be carried forward into the second
round and any additional outcomes suggested by partici-
pants will be included. Participants will receive their
own scores and stakeholder group feedback for each
round-1 outcome. Participants will be invited to reflect
and rescore individual outcomes.
Round 3
All outcomes will be carried forward into the third
round. Participants will receive their own scores and
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stakeholder group feedback for each round-2 outcome.
Participants will be invited to reflect and rescore individ-
ual outcomes. A standardized definition will be applied
to this round’s results enabling consensus outcomes to
be identified. Consensus outcomes will be defined as
outcomes achieving a median score of 8 across all three
stakeholder groups.
Stakeholder meeting: modified Nominal Group Technique
The results of the Delphi survey will be discussed in a
consensus development meeting including professionals,
researchers and people with lived experience of sFGR.
The round-3 results will be reviewed and all consensus
outcomes will be considered. Participants will be able to
discuss any other outcomes upon request. The objective
of the consensus development meeting will be to de-
velop a final core outcome set for sFGR.
Determining core outcome measures
Once the core outcome set has been agreed and estab-
lished it will be necessary to determine how it should be
defined or measured. Potential definitions and measure-
ment instruments will be inventoried across formal defin-
ition development initiatives, national and international
guidelines, Cochrane systematic reviews and published
studies. Potential definitions will be entered into a consen-
sus development workshop including professionals, re-
searchers and people with lived experience of sFGR. The
objective of the consensus workshop will be to identify
definitions for individual core outcomes. Potential meas-
urement instruments will be quality assessed using the
Core Outcome Measures in Effectiveness Trials (COMET)
and the Consensus-Based Standards for the Selection of
Health Measurement Instruments (COSMIN) Initiative
quality assessment framework [29].
Dissemination and implementation
The Steering Group will aim to disseminate the core
outcome set as widely and effectively as possible. We
will aim to describe the core outcome set through publi-
cation in a relevant journal as well as presenting to our
peers at meetings. The Core Outcomes in Women’s and
Newborn’s Health (CROWN) Initiative is endorsed by
the International Federation of Gynecology and Obstet-
rics (FIGO), the Royal College of Obstetricians and
Gynaecologists (RCOG), and the Royal Australian and
New Zealand College of Obstetricians and Gynaecolo-
gists (RANZCOG). TAMBA will use its publicity chan-
nels to further share the core outcome set to both health
care professionals and patients. With the CROWN Ini-
tiative now supported by over 80 journals, researchers
will have more obligation to engage with the core out-
come set when it comes to planning their studies. We
will also engage with the relevant Cochrane Review
Groups, clinical guideline developers, research funders,
trial registries and regulators such as research ethics
committees. We plan to use a theoretically informed
framework when implementing dissemination [30].
The methods of dissemination we are planning to use
are peer-reviewed publications in open-access jour-
nals, presentations at scientific meetings, posters,
events, newsletters, press release, and podcasts. We
will report the core outcome set in line with the
COS-STAR Statement [31].
Discussion
The development and implementation of core outcome
sets is likely to be very beneficial to the design and
reporting of clinical studies, systematic reviews, and clin-
ical guideline. This should ultimately improve clinical
care and patients’ experience. The importance of such
an initiative has been acknowledged by a number of key
national and international organizations.
Improving the selection of the outcome of clinical studies
The Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) Statement, supported by
funders of health research, such as the National Institute
of Health Research (NIHR), recommends the use of core
outcome sets. The use of standard core outcome sets
would enhance comparability of clinical trials and facili-
tate the conduct of prospective meta-analyses using indi-
vidual patient data.
Facilitating the evidence synthesis and reporting of
clinical studies
The Core Outcomes in Women’s and Newborn’s Health
(CROWN) Initiative, supported by 78 specialty journals,
including the Cochrane Pregnancy and Childbirth
Group, has resolved to implement core outcome sets.
These journals would expect authors to report the study
results for the core outcomes and draw their conclusions
based on these outcomes rather than non-core or surro-
gate outcomes.
Enhancing the ability to develop robust clinical guidelines
The National Institute for Health and Care Excellence
(NICE) supports the use of core outcome sets during
evidence scoping and synthesis [32, 33]. The NICE
methodology of assessment of the quality of the evi-
dence takes into account whether the data of interest
were reported as a core, non-core or surrogate outcome.
This initiative to improve the quality and consistency of
outcomes investigated and reported by researchers can
in turn lead to the development of guidelines based on
clearer and stronger evidence to help all clinicians offer
the best interventions for their patients.
Khalil et al. Trials           (2019) 20:35 Page 5 of 7
Developing a network which can support an international
collaboration
The team of involved key stakeholders has the potential
to set up an international network, which could be a po-
tent vehicle for the development of international guide-
lines and registries and setting research priorities for
sFGR. In the context of sFGR, this could potentially have
a profound impact on morbidity and mortality rates in
the long term.
Trial status
At the time of manuscript submission, the systematic re-
view process has commenced and strategic planning for
the Delphi method consensus-building exercise is under-
way. This is the first version of the protocol (18th April
2018).
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